CD4 and neoplasm: Moreover, SC144@HABN + anti-PD-L1 combo therapy significantly decreased the frequency of CD4+FoxP3+ regulatory T-cells (Fig. 4h) and CD45-PD-L1+ tumor cells in the TME (Fig. 4i), compared with other groups.